Navigation Links
China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results
Date:6/1/2011

BEIJING, June 1, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, announced its unaudited financial results for the fourth fiscal quarter ("4Q FY2010") and the full fiscal year ended March 31, 2011 ("FY2010") today.4Q FY2010 HighlightsFor the Three Months EndedMarch 31, 2010March 31, 2011March 31, 2011RMBRMBUS$% change(in thousands except for per ADS information)Net revenues175,728230,41435,18731.1%Net income4,82016,0952,458233.9%Diluted earnings per ADS*0.190.610.09221.1%Non-GAAP net income51,47675,00211,45445.7%Non-GAAP diluted earnings per ADS*1.982.840.4343.4%Adjusted EBITDA99,591140,24421,41740.8%FY2010 HighlightsFor the Year EndedMarch 31, 2010March 31, 2011March 31, 2011RMBRMBUS$% change(in thousands except for per ADS information)Net revenues723,071842,366128,63916.5%Net income (loss)(69,582)82,61912,617-Diluted earnings (loss) per ADS*(2.65)3.140.48-Non-GAAP net income187,295273,05641,69945.8%Non-GAAP diluted earnings per ADS*7.1310.391.5945.7%Adjusted EBITDA387,580493,25475,32627.3%Outlookfor first fiscal quarter ending June 30, 2011

  • Target net revenues are expected to range from RMB232.0 million (US$35.4 million) to RMB234.0 million (US$35.7 million), representing a year-over-year increase of 24.6% - 25.7%.
  • Target non-GAAP net income is expected to range from RMB73.0 million (US$11.1 million) to RMB74.0 million (US$11.3 million), representing a year-over-year increase of 28.0% - 29.8%.
  • Target non-GAAP diluted earnings per ADS* is expected to range from RMB2.75 (US$0.42) to RMB2.79 (US$0.43), representing a year-over-year increase of 26.1% - 28.0%.

  • Outlook for full fiscal year ending March 31, 2012

  • Target net revenues are expected to range from RMB970.0 million (US$148.1 million) to RMB995.0 million (US$151.9 million), representing a year-over-year increase of 15.2% - 18.1%.
  • Target non-GAAP net income is expected to range from RMB310.0 million (US$47.3 million) to RMB318.0 million (US$48.6 million), representing a year-over-year increase of 13.5% - 16.5%. The slightly lower growth rate in non-GAAP net income is primarily due to the full year impact of additional interest expense arising from new convertible notes issued in December 2010.
  • Target non-GAAP diluted earnings per ADS* is expected to range from RMB11.70 (US$1.79) to RMB12.00 (US$1.83), representing a year-over-year increase of 12.6% - 15.5%.

  • The above targets are based on the Company's current views on the operating and market conditions, which are subject to change.

    *One American Depositary Share ("ADS") = 10 ordinary shares

    See "Non-GAAP Measure Disclosures" below, where the impact of certain items on reported results is discussed.

    "We are pleased with the quarterly results, in particular, the continued growth of our molecular diagnostic business during the seasonally weak quarter. We expect our FISH business and HPV-DNA chip business to drive our growth in the following quarters," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We will continue to expand our product offering in FISH probes and PCR assays as well as develop a new SPR analyzer through investment in research and development. We will leverage our established sales networks to introduce our new products to our hospital customers. In addition, we are working on several initiatives to support our sustainable growth including discussion with a leading independent laboratory testing service group in China for a potential collaboration to promote the use of molecular diagnostic tests to the group's hospital customers."

    Mr. Sam Tsang, Chief Financial Officer of the Company commented, "We issued new convertible notes in December 2010 to extend our debt maturity profile. We have been focusing to improve our leverage profile and have reduced our net debt to adjusted EBITDA ratio from 5.1 times to 3.3 times. However, we believe that we are still maintaining relatively high leverage, and the continued improvement in our leverage to the level of 2 times or below is our priority. We have been very cautious in making capital expenditures and did not consider new acquisition and will continue to do so. Meanwhile, we will maintain our investment in product research and development which will support our future growth. We will also continue to invest in our direct sales network to attract and retain Tier 1 hospitals which are major consumers in China's healthcare industry."

    4Q FY2010 Unaudited Financial ResultsThe Company reported net revenues of RMB230.4 million (US$35.2 million) for 4Q FY2010, representing a 31.1% increase from the corresponding period of FY2009.

    The Company's revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products. The customers of the molecular diagnostic system segment, that is, Tier 1 hospitals in China, are being served by the Company's direct sales personnel.

    Molecular diagnostic system sales for 4Q FY2010 were RMB146.6 million (US$22.4 million), representing a 45.3% increase from the corresponding period of FY2009. The year-over-year increase was primarily due to the increase in usage of the Company's FISH probes by existing and new hospital customers as well as the sales of SPR-based HPV-DNA chips of RMB11.9 million (US$1.8 million) to hospitals during 4Q FY2010.

    Immunodiagnostic system sales for 4Q FY2010 were RMB83.8 million (US$12.8 million), representing a 12.0% increase from the corresponding period of FY2009. The year-over-year increase was primarily due to the increase in sales of the Company's ECLIA reagent kits to existing and new distributors.

    Gross margin was 61.4% for 4Q FY2010 which decreased year-over-year from 64.9% for the corresponding period of FY2009. The year-over-year decrease was primarily due to the classification of amortization of SPR intangible assets from operating expenses to cost of revenues after the commencement of sales of HPV-DNA chips in 2Q FY2010 which offset the positive impact on more contribution from the sales of FISH probes which generate higher gross margin. Non-GAAP gross margin was 82.4% for 4Q FY2010 which increased year-over-year from 77.7% for the corresponding period of FY2009. The year-over-year increase in non-GAAP gross margin was primarily due to more contribution from the sales of FISH probes which generate higher gross margin.

    Research and development expenses were RMB12.6 million (US$1.9 million) for 4Q FY2010, representing a 21.8% year-over-year increase. Non-GAAP research and development expenses were RMB11.4 million (US$1.7 million) for 4Q FY2010, representing a 28.0% year-over-year increase. The year-over-year increase was primarily due to product research and development for SPR analyzers and PCR assays.

    Sales and marketing expenses were RMB24.0 million (US$3.7 million) for 4Q FY2010, representing a 43.9% year-over-year increase. Non-GAAP sales and marketing expenses were RMB23.8 million (US$3.6 million) for 4Q FY2010, representing a 42.7% year-over-year increase. The year-over-year increase was primarily due to an increase in direct sales efforts for molecular diagnostic systems.

    General and administrative expenses were RMB25.4 million (US$3.9 million) for 4Q FY2010, representing a 5.1% year-over-year decrease. Non-GAAP general and administrative expenses were RMB18.4 million (US$2.8 million) for 4Q FY2010, representing a 5.0% year-over-year increase.

    Interest expense on convertible notes was RMB34.6 million (US$5.3 million) for 4Q FY2010. Non-GAAP interest expense on convertible notes was RMB33.2 million (US$5.1 million) for 4Q FY2010. As of March 31, 2011, the Company's outstanding convertible notes of US$22.7 million, US$248.0 million and US$150.0 million bear interest at 3.5%, 4% and 6.25% per annum, respectively, and will mature in November 2011, August 2013 and December 2016, respectively.

    Interest expense related to amortization of convertible notes issuance costs was RMB4.2 million (US$0.6 million) for 4Q FY2010.

    Interest expense related to amortization of share lending costs was RMB2.4 million (US$0.4 million) for 4Q FY2010.

    Income tax expense was RMB28.1 million (US$4.3 million) for 4Q FY2010. The high effective tax rate was due to certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax purpose. In addition, the Company was required to accrue for withholding income tax on distributable earnings generated in China.

    Net income was RMB16.1 million (US$2.5 million) for 4Q FY2010, which improved significantly from RMB4.8 million for the corresponding period of FY2009. Non-GAAP net income was RMB75.0 million (US$11.5 million) for 4Q FY2010, representing a 45.7% increase from the corresponding period of FY2009. The significant year-over-year increase was primarily due to the increase in both molecular diagnostic system sales and immunodiagnostic system sales.

    Earnings before interest, taxes, depreciation and amortization ("EBITDA") was RMB133.3 million (US$20.4 million) for 4Q FY2010, representing an 18.0% increase from the corresponding period of FY2009. The year-over-year increase in EBITDA was primarily due to the increase in both molecular diagnostic system sales and immunodiagnostic system sales.

    Adjusted EBITDA was RMB140.2 million (US$21.4 million) for 4Q FY2010, representing a 40.8% increase from the corresponding period of FY2009. The reason for the increase is also due to increased sales in 4Q FY2010.

    Stock compensation expense for 4Q FY2010 was RMB8.5 million (US$1.3 million), of which RMB0.1 million was allocated to cost of revenues, RMB1.2 million to research and development expenses, RMB0.2 million to sales and marketing expenses and RMB7.0 million to general and administrative expenses.

    Amortization of acquired intangible assets for 4Q FY2010 was RMB48.2 million (US$7.4 million) which was all allocated to cost of revenues.

    As of March 31, 2011, the Company's cash and cash equivalents were RMB1,123.8 million (US$171.6 million). Net cash generated from operating activities for 4Q FY2010 was RMB37.3 million (US$5.7 million). Net cash generated from investing activities for 4Q FY2010 was RMB18.8 million (US$2.9 million). Net cash used in financing activities for 4Q FY2010 was RMB48.9 million (US$7.5 million).

    As of March 31, 2011, the Company's net accounts receivable was RMB481.1 million (US$73.5 million), representing an increase of 21.0% from the balance at December 31, 2010. The increase in net accounts receivable was primarily due to the increase in molecular diagnostic system sales to hospital customers.

    FY2010 Unaudited Financial Results Net revenues were RMB842.4 million (US$128.6 million) for FY2010, representing a 16.5% year-over-year increase. The year-over-year increase in revenues was primarily due to the increase in molecular diagnostic system sales.

    Gross margin was 60.3% for FY2010 which decreased year-over-year from 67.1% for FY2009. The year-over-year decrease was primarily due to the classification of amortization of SPR intangible assets from operating expenses to cost of revenues after the commencement of sales of HPV-DNA chips in 2Q FY2010 which offset the positive impact on more contribution from the sales of FISH probes which generate higher gross margin. Non-GAAP gross margin was 80.3% for FY2010 which increased year-over-year from 79.6% for FY2009. The year-over-year increase in non-GAAP gross margin was primarily due to more contribution from the sales of FISH probes which generate higher gross margin.

    Research and development expenses were RMB46.5 million (US$7.1 million) for FY2010, representing a 9.9% year-over-year increase. Non-GAAP research and development expenses were RMB41.5 million (US$6.3 million) for FY2010, representing a 15.5% year-over-year increase. The year-over-year increase was primarily due to product research and development for FISH probes, SPR analyzers and PCR assays.

    Sales and marketing expenses were RMB88.2 million (US$13.5 million) for FY2010, representing a 37.7% year-over-year increase. Non-GAAP sales and marketing expenses were RMB87.5 million (US$13.4 million) for FY2010, representing a 36.6% year-over-year increase. The year-over-year increase was primarily due to an increase in direct sales efforts for molecular diagnostic systems.

    General and administrative expenses were RMB96.6 million (US$14.7 million) for FY2010, representing a 33.3% year-over-year decrease. Non-GAAP general and administrative expenses were RMB65.4 million (US$10.0 million) for FY2010, representing a 40.8% year-over-year decrease. The year-over-year decrease was primarily because the Company incurred costs for the independent internal investigation in FY2009 which did not recur in FY2010.

    Net income was RMB82.6 million (US$12.6 million) for FY2010, which improved significantly from net loss of RMB69.6 million for FY2009. Non-GAAP net income was RMB273.1 million (US$41.7 million) for FY2010, representing a 45.8% year-over-year increase from FY2009.

    EBITDA was RMB531.2 million (US$81.1 million) for FY2010, representing a 43.1% year-over-year increase from FY2009.

    Adjusted EBITDA was RMB493.3 million (US$75.3 million) for FY2010, representing a 27.3% year-over-year increase from FY2009.

    Stock compensation expense for FY2010 was RMB37.2 million (US$5.7 million), of which RMB0.4 million was allocated to cost of revenues, RMB4.9 million to research and development expenses, RMB0.7 million to sales and marketing expenses and RMB31.2 million to general and administrative expenses.

    Amortization of acquired intangible assets for FY2010 was RMB196.0 million (US$29.9 million), of which RMB168.7 million was allocated to cost of revenues and RMB27.3 million to operating expenses.

    For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.5483 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, March 31, 2011. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on March 31, 2011 or at any other dates.

    Product Development PlanThe Company plans to focus on the following product development activities with respect to its molecular diagnostic products:

    FISH

  • to develop more applications in the areas of prenatal diagnosis, cancer detection and companion diagnostics for cancer targeted drugs through internal research and development.

  • SPR

  • to develop a new automated analyzer for hospitals and independent laboratories to conduct HPV tests using our DNA chips through internal research and development.

  • PCR

  • to develop more assays in the area of companion diagnostics for cancer targeted drugs through internal research and development.

  • Update on Receivable from ChengxuanAs of March 31, 2011, the remaining amount of the receivable from Chengxuan, a company which is one of the Company's major shareholders and is owned by Mr. Xiaodong Wu, was reduced from US$18 million to US$15 million. This receivable relates to the sale of the Company's HIFU business to Chengxuan. Subsequently, Chengxuan paid US$8 million to the Company and indicated that the remaining balance of US$7 million together with interest thereon will be paid in full before June 30, 2011.

    Non-GAAP Measure DisclosuresThe Company reported its operating results in accordance with U.S. generally accepted accounting principles ("GAAP") for the three months and the year ended March 31, 2010 and 2011, respectively. The Company also presented non-GAAP information, which included EBITDA and adjusted EBITDA, for the three months and the year ended March 31, 2010 and 2011, respectively. The non-GAAP measures are defined below:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, excluding the effects of stock compensation expense and amortization of acquired intangible assets.

  • Non-GAAP gross margin represents non-GAAP gross profit divided by net revenues.

  • Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, excluding the effects of stock compensation expense.

  • Non-GAAP sales and marketing expenses represent sales and marketing expenses reported in accordance with GAAP, excluding the effects of stock compensation expense.

  • Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, excluding the effects of stock compensation expense.

  • Non-GAAP operating income represents operating income reported in accordance with GAAP, excluding the effects of stock compensation expense and amortization of acquired intangible assets.

  • Non-GAAP interest expense on convertible notes represents interest expense on convertible notes reported in accordance with GAAP, excluding the effects of non-cash interest expense of convertible notes.

  • Non-GAAP interest expense on amortization of share lending costs represents the exclusion of interest expense on amortization of share lending costs reported in accordance with GAAP, as this item is non-cash.

  • Non-GAAP other income (expense), net represents other income and expense, net reported in accordance with GAAP, excluding the effects of gain on repurchase of convertible notes as well as high yield note offering expenses.

  • Non-GAAP net income represents net income reported in accordance with GAAP, excluding the effects of stock compensation expense, amortization of acquired intangible assets, non-cash interest expense of convertible notes, interest expense for amortization of share lending costs, gain on repurchase of convertible notes as well as high yield note offering expenses.

  • Non-GAAP earnings per ADS represents non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.

  • EBIT represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense and income tax expense.

  • EBITDA represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense, income tax expense, depreciation and amortization.

  • Adjusted EBITDA represents EBITDA excluding the effects of stock compensation expense, gain on repurchase of convertible notes as well as high yield note offering expenses.

  • Non-GAAP financial measures are used by the Company in its financial and operating decision-making because management believes they reflect the Company's ongoing business in a manner that allows meaningful period-to-period comparison. The Company's management believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company's current operating performance and future prospects in the same manner as management does, if they so choose.

    The presentation of this additional financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the financial information included with this earnings announcement.

    Conference CallThe Company's senior management team will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on June 2, 2011 (or 8:00 p.m. Beijing/Hong Kong time on the same date) to discuss the results following this earnings announcement.

    The dial-in details for the live conference call are as follows:

    -
    U.S. Toll Free Number 1-800-215-2410-
    International Dial-in Number 1-617-597-5410Passcode: CMEDCALLA live webcast of the conference call will be available on http://ir.chinameditech.com.

    A replay of this webcast will be available for one month on this website.

    A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S. Eastern Time on June 3, 2011.  

    The dial-in details for the replay are as follows:

    -
    U.S. Toll Free Number 1-888-286-8010-
    International Dial-in Number 1-617-801-6888Passcode: 61583099A
    bout China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.

    Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release, as well as its outlook for the first fiscal quarter ending June 30, 2011 and full fiscal year ending March 31, 2012, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    ContactsSam Tsang and Winnie YamTel: 852-2511-9808Email: IR@chinameditech.comChina Medical Technologies, Inc.Unaudited Condensed Consolidated Balance SheetsAs ofDecember 31, 2010March 31, 2011RMBRMBUS$(in thousands)AssetsCurrent assetsCash and cash equivalents

    1,119,3841,123,818171,620Trade accounts receivable, net

    397,739481,09673,469Inventories

    16,64019,2732,943Prepayments and other receivables

    10,52118,9522,894Due from a related party

    118,80098,22515,000Total current assets

    1,663,0841,741,364265,926Property, plant and equipment, net

    144,251139,44821,295Land use rights

    6,9066,8591,047Goodwill

    8,6548,6541,322Intangible assets, net 

    3,042,4742,973,358454,066Convertible notes issuance costs

    60,16355,8178,524Share lending costs

    25,13322,5623,445Total assets

    4,950,6654,948,062755,625Liabilities Current liabilitiesTrade accounts payable

    44,47744,5026,796Accrued liabilities and other payables 

    174,978191,12029,186Convertible notes

    186,763146,08122,308Income taxes payable

    63,85977,95411,904Total current liabilities

    470,077459,65770,194Convertible notes

    2,626,8002,606,223398,000Deferred income taxes

    84,93691,59613,988Total liabilities

    3,181,8133,157,476482,182Shareholders' equityOrdinary shares US$0.1 par value:500,000,000 authorized; 322,680,001 issued and 
    outstanding as of December 31, 2010 and March 31,
    2011

    258,840258,84039,528Additional paid-in capital

    869,439875,448133,691Treasury stock

    (201,362)(201,362)(30,750)Accumulated other comprehensive loss

    (76,923)(77,293)(11,804)Retained earnings

    918,858934,953142,778Total shareholders' equity

    1,768,8521,790,586273,443Total liabilities and shareholders' equity

    4,950,6654,948,062755,625China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Income andReconciliations of GAAP Measures to Non-GAAMeasuresFor the Three Months EndedFor the Three Months EndedMarch 31, 2010March 31, 2011GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRMBRMBRMBRMBRMBRMBAs adjusted 
    (9)(in thousands except for per ADS information)Net revenues (1)

    175,728-175,728230,414-230,414Cost of revenues (2)

    (61,624)22,423(39,201)(88,948)48,295(40,653)Gross profit

    114,10422,423136,527141,46648,295189,761Operating expensesResearch anddevelopment (3)

    (10,352)1,440(8,912)(12,612)1,208(11,404)Sales and marketing (3)

    (16,695)-(16,695)(24,017)192(23,825)General andadministrative (3)

    (26,743)9,252(17,491)(25,381)7,009(18,372)Amortization ofSPR intangibleassets (4)

    (27,343)27,343----Total operating expenses

    (81,133)38,035(43,098)(62,010)8,409(53,601)Operating income

    32,97160,45893,42979,45656,704136,160Interest income

    4,155-4,1555,779-5,779Interest expense –convertible notes (5)

    (34,831)7,618(27,213)(34,612)1,387(33,225)Interest expense – 
    amortization of 
    convertible notes 
    issuance costs

    (4,263)-(4,263)(4,150)-(4,150)Interest expense –amortization ofshare lending costs (6)

    (2,644)2,644-(2,386)2,386-Other income (expense),net (7)

    24,638(24,064)574144(1,570)(1,426)Income beforeincome tax

    20,02646,65666,68244,23158,907103,138Income tax expense

    (15,206)-(15,206)(28,136)-(28,136)Net income

    4,82046,65651,47616,09558,90775,002Earnings per ADS- basic (8)

    0.191.791.980.612.252.86- diluted (8)

    0.191.791.980.612.232.84Weighted averagenumber of ADS- basic (8)

    25,993,349-25,993,34926,184,308-26,184,308- diluted (8)

    26,050,599-26,050,59926,448,663-26,448,663China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Income andReconciliations of GAAP Measures to Non-GAAMeasuresConvenience Translation for Reference OnlyFor the Three Months EndedMarch 31, 2011GAAPAdjustmentsNon-GAAPUS$US$US$(in thousands except for per ADS information)Net revenues (1)

    35,187-35,187Cost of revenues (2)

    (13,583)7,375(6,208)Gross profit

    21,6047,37528,979Operating expensesResearch and development (3)

    (1,926)185(1,741)Sales and marketing (3)

    (3,668)30(3,638)General and administrative (3)

    (3,876)1,070(2,806)Amortization of SPR intangible assets (4)

    ---Total operating expenses

    (9,470)1,285(8,185)Operating income

    12,1348,66020,794Interest income

    883-883Interest expense – convertible notes (5)

    (5,286)212(5,074)Interest expense – amortization ofconvertible notes issuance costs

    (634)-(634)Interest expense – amortization ofshare lending costs (6)

    (364)364-Other income (expense), net (7)

    22(240)(218)Income before income tax

    6,7558,99615,751Income tax expense

    (4,297)-(4,297)Net income

    2,4588,99611,454Earnings per ADS- basic (8)

    0.090.350.44- diluted (8)

    0.090.340.43Weighted average number of ADS- basic (8)

    26,184,308-26,184,308- diluted (8)

    26,448,663-26,448,663For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of
    RMB6.5483 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as
    set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, March 31, 2011.
    No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at
    that rate or at any other rate on March 31, 2011 or at any other dates.Notes:For
     the Three Months EndedMarch 31, 2010March 31, 2011(1)
    Net revenues

    RMB'000RMB'000US$'000- Molecular diagnostic systems

    100,897146,63522,393- Immunodiagnostic systems

    74,83183,77912,794175,728230,41435,187Molecular diagnostic systems- HPV-DNA chips

    -11,9221,821(2) Non-GAAP numbers exclude stock compensation expense and amortization of acquired intangible assets.For the Three Months EndedMarch 31, 2010March 31, 2011RMB'000RMB'000US$'000Stock compensation expense

    -11017Amortization of acquired intangible assets22,42348,1857,35822,42348,2957,375(3) Non-GAAP numbers exclude stock compensation expense.(4) Non-GAAP numbers exclude amortization of acquired intangible assets.(5) Non-GAAP numbers exclude non-cash interest expense of convertible notes.(6) Non-GAAP numbers exclude interest expense for amortization of share lending costs. (7) Non-GAAP numbers exclude gain on repurchase of convertible notes.For the Three Months EndedMarch 31, 2010March 31, 2011RMB'000RMB'000US$'000Gain on repurchase of convertible notes24,0641,570240(8) Interest expense and amortization in connection with convertible notes were not added back in computing GAAP diluted earnings per ADS because they were anti-dilutive. Non-GAAP earnings per ADS represents non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.(9) As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or other financing, effective on April 1, 2010,  the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months ended March 31, 2010 retrospectively in accordance with GAAP.China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Income andReconciliations of GAAP Measures to Non-GAAMeasuresFor the Year EndedFor the Year EndedMarch 31, 2010March 31, 2011GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRMBRMBRMBRMBRMBRMBAs adjusted
    (9)(in thousands except for per ADS information)Net revenues (1)

    723,071-723,071842,366-842,366Cost of revenues (2)

    (237,550)89,720(147,830)(334,682)169,086(165,596)Gross profit

    485,52189,720575,241507,684169,086676,770Operating expensesResearch anddevelopment (3)

    (42,293)6,335(35,958)(46,469)4,946(41,523)Sales and marketing (3)

    (64,055)-(64,055)(88,182)672(87,510)General andadministrative (3)

    (144,671)34,102(110,569)(96,567)31,151(65,416)Amortization ofSPR intangibleassets (4)

    (109,395)109,395-(27,329)27,329-Total operating expenses

    (360,414)149,832(210,582)(258,547)64,098(194,449)Operating income

    125,107239,552364,659249,137233,184482,321Interest income

    13,456-13,45620,882-20,882Interest expense –convertible notes (5)

    (141,123)30,477(110,646)(131,918)22,628(109,290)Interest expense – 
    amortization of 
    convertible notes 
    issuance costs

    (17,402)-(17,402)(16,009)-(16,009)Interest expense –amortization ofshare lending costs (6)

    (10,912)10,912-(9,731)9,731-Other income (expense),net (7)

    24,848(24,064)78464,086(75,106)(11,020)Income (loss) beforeincome tax

    (6,026)256,877250,851176,447190,437366,884Income tax expense

    (63,556)-(63,556)(93,828)-(93,828)Net income (loss)

    (69,582)256,877187,29582,619190,437273,056Earnings (loss) per ADS- basic (8)

    (2.65)9.787.133.167.3010.46- diluted (8)

    (2.65)9.787.133.147.2510.39Weighted averagenumber of ADS- basic (8)

    26,254,639-26,254,63926,114,768-26,114,768- diluted (8)

    26,254,639-26,254,63926,280,000-26,280,000China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Income andReconciliations of GAAP Measures to Non-GAAMeasuresConvenience Translation for Reference onlyFor the Year EndedMarch 31, 2011GAAPAdjustmentsNon-GAAPUS$US$US$(in thousands except for per ADS information)Net revenues (1)

    128,639-128,639Cost of revenues (2)

    (51,110)25,822(25,288)Gross profit

    77,52925,822103,351Operating expensesResearch and development (3)

    (7,096)755(6,341)Sales and marketing (3)

    (13,466)103(13,363)General and administrative (3)

    (14,747)4,757(9,990)Amortization of SPR intangible assets (4)

    (4,173)4,173-Total operating expenses

    (39,482)9,788(29,694)Operating income

    38,04735,61073,657Interest income

    3,189-3,189Interest expense – convertible notes (5)

    (20,145)3,455(16,690)Interest expense – amortization ofconvertible notes issuance costs

    (2,445)-(2,445)Interest expense – amortization ofshare lending costs (6)

    (1,486)1,486-Other income (expense), net (7)

    9,786(11,469)(1,683)Income before income tax

    26,94629,08256,028Income tax expense

    (14,329)-(14,329)Net income

    12,61729,08241,699Earnings per ADS- basic (8)

    0.481.121.60- diluted (8)

    0.481.111.59Weighted average number of ADS- basic (8)

    26,114,768-26,114,768- diluted (8)

    26,280,000-26,280,000For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of
    RMB6.5483 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar
    as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, March 31,
    2011. No representation is made that the RMB amounts could have been or could be converted into U.S.
    dollars at that rate or at any other rate on March 31, 2011 or at any other dates.Notes:For
     the Year EndedMarch 31, 2010March 31, 2011(1)
    Net revenues

    RMB'000RMB'000US$'000- Molecular diagnostic systems

    384,762508,16277,602- Immunodiagnostic systems

    338,309334,20451,037723,071842,366128,639Molecular diagnostic systems- HPV-DNA chips

    -24,9283,807(2) Non-GAAP numbers exclude stock compensation expense and amortization of acquired intangible assets.For the Year EndedMarch 31, 2010March 31, 2011RMB'000RMB'000US$'000Stock compensation expense

    -38559Amortization of acquired intangible assets89,720168,70125,76389,720169,08625,822(3) Non-GAAP numbers exclude stock compensation expense.(4) Non-GAAP numbers exclude amortization of acquired intangible assets.(5) Non-GAAP numbers exclude non-cash interest expense of convertible notes. (6) Non-GAAP numbers exclude interest expense for amortization of share lending costs. (7) Non-GAAP numbers exclude gain on repurchase of convertible notes as well as high yield note offering expenses.For the Year EndedMarch 31, 2010March 31, 2011RMB'000RMB'000US$'000Gain on repurchase of convertible notes24,06480,34212,269High yield note offering expenses

    -(5,236)(800)24,06475,10611,469(8) Interest expense and amortization in connection with convertible notes were not added back in computing GAAP diluted earnings per ADS because they were anti-dilutive. Non-GAAP earnings per ADS represents non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.(9) As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or other financing, effective on April 1, 2010,  the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the year ended March 31, 2010 retrospectively in accordance with GAAP.China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Cash FlowsFor the Three Months EndedMarch 31, 2010March 31, 2011RMBRMBUS$(in thousands)Net cash provided by operating activities

    59,75837,3395,702Net cash provided by (used in) investing activities

    (609)18,7892,869Net cash used in financing activities

    (73,596)(48,921)(7,471)Effect of foreign currency exchange rate change on cashand cash equivalents

    13(2,773)(423)Net increase (decrease) in cash and cash equivalents

    (14,434)4,434677Cash and cash equivalents:At beginning of period

    829,8871,119,384170,943At end of period

    815,4531,123,818171,620For the Year EndedMarch 31, 2010March 31, 2011RMBRMBUS$(in thousands)Net cash provided by operating activities

    279,877224,17634,234Net cash provided by (used in) investing activities

    (715,522)94,16914,381Net cash used in financing activities

    (205,061)(3,000)(458)Effect of foreign currency exchange rate change on cashand cash equivalents

    (251)(6,980)(1,066)Net increase (decrease) in cash and cash equivalents

    (640,957)308,36547,091Cash and cash equivalents:At beginning of period

    1,456,410815,453124,529At end of period

    815,4531,123,818171,620China Medical Technologies, Inc.EBITDA and Adjusted EBITDA MeasuresFor the Three Months EndedMarch 31, 2010March 31, 2011RMBRMBUS$As adjusted (1)(in thousands)Net income

    4,82016,0952,458Adjustments:Interest income

    (4,155)(5,779)(883)Interest expense – convertible notes

    34,83134,6125,286Interest expense – amortization of convertible 
    notes issuance costs

    4,2634,150634Interest expense – amortization of share 
    lending costs

    2,6442,386364Income tax expense

    15,20628,1364,297EBIT (2)

    57,60979,60012,156Adjustments:Depreciation

    5,5885,510842Amortization

    49,76648,1857,358EBITDA (3)

    112,963133,29520,356EBITDA (3)

    112,963133,29520,356Adjustments:Stock compensation expense

    10,6928,5191,301Gain on repurchase of convertible notes

    (24,064)(1,570)(240)Adjusted EBITDA (4)

    99,591140,24421,417For the Year EndedMarch 31, 2010March 31, 2011RMBRMBUS$As adjusted (1)(in thousands)Net income (loss)

    (69,582)82,61912,617Adjustments:Interest income

    (13,456)(20,882)(3,189)Interest expense – convertible notes

    141,123131,91820,145Interest expense – amortization of convertible 
    notes issuance costs

    17,40216,0092,445Interest expense – amortization of share 
    lending costs

    10,9129,7311,486Income tax expense

    63,55693,82814,329EBIT (2)

    149,955313,22347,833Adjustments:Depreciation

    22,13721,9533,352Amortization

    199,115196,03029,936EBITDA (3)

    371,207531,20681,121EBITDA (3)

    371,207531,20681,121Adjustments:Stock compensation expense

    40,43737,1545,674Gain on repurchase of convertible notes(24,064)(80,342)(12,269)High yield note offering expenses

    -5,236800Adjusted EBITDA (4)

    387,580493,25475,326Notes:(1) As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or other financing effective on April 1, 2010, the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months and the year ended March 31, 2010 retrospectively in accordance with GAAP.(2) EBIT represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense and income tax expense.(3) EBITDA represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense, income tax expense, depreciation and amortization.(4) Adjusted EBITDA represents EBITDA excluding the effects of stock compensation expense, gain on repurchase of convertible notes as well as high yield note offering expenses.
    '/>"/>

    SOURCE China Medical Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... BIRMINGHAM, Ala. , Feb. 5, 2016  Patients in ... invasive high intensity focused ultrasound (HIFU) therapy no longer have ... pleased to announce its partnership with Urology Centers of ... includes the newly FDA-cleared procedure for qualifying patients. ... for their expertise in the treatment of prostate cancer using ...
    (Date:2/5/2016)... Feb. 5, 2016  Venice,s newest laser clinic, ... first of its kind in the area and ... advanced laser treatment. The physician-owned and operated laser ... Suncoast by storm with its revitalizing skin care ... multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
    (Date:2/5/2016)... February 5, 2016 --> ... research report "Fetal (Labor & Delivery) and Neonatal Care ... Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & ... This report studies the global market over the forecast ... at USD 6.28 Billion in 2015 and is poised ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to feel ... be safer than regular municipal or well water. The recent experience with lead contaminated ... could go a long way toward increasing public acceptance of recycled waste water as ...
    (Date:2/5/2016)... , ... February 05, 2016 , ... Boar’s Head Brand®, ... in time for this weekend’s Big Game. Take the stress out of your party ... keep your guests happy at every stage of the game. , “The key to ...
    (Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
    (Date:2/5/2016)... ... 05, 2016 , ... Colorize is a web theme package created ... next using Colorize's dynamic moving camera. Colorize is perfect for personal and web related ... environment with 1 to 5 focus points per scene, stage floor scene presets that ...
    (Date:2/5/2016)... ... ... California Mobile Kitchens , a company that designs ... kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. , ... in the U.S. Many of their units can be seen at sporting events, ...
    Breaking Medicine News(10 mins):